Eli Lilly's Zepbound and Taltz Combo Shows Promise for Psoriatic Arthritis and Obesity
TL;DR Summary
Eli Lilly's drug Zepbound, when combined with its immunology therapy Taltz, showed promise in reducing symptoms of psoriatic arthritis in obese patients, suggesting potential new uses for the weight loss drug, though its impact on prescribing patterns remains uncertain.
- Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms statnews.com
- Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight Eli Lilly
- Lilly touts promise of Zepbound-Taltz combo in patients with obesity and psoriatic arthritis Fierce Pharma
- Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial Reuters
- Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom TechStock²
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 1 min read
Condensed
78%
179 → 39 words
Want the full story? Read the original article
Read on statnews.com